Market Access UCB brings first therapy for rare disease TK2d to EU PharmaphorumThe EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.Market AccessRare DiseaseRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum The EU has approved UCB’s Kygevvi for rare disease TK2d, and Sanofi’s acute GvHD therapy Rezurock, in a pair of decisions announced this morning. Market AccessRare DiseaseRead full story Post navigation Previous: Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team PhotoNext: Merck strikes deal with antibody discovery startup Related Stories Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026 Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026
